This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Pancreatic cancer	Not applicable	<p>Mouse studies suggest radionuclide-labeled <i>Listeria monocytogenes</i> could help treat metastatic pancreatic cancer. In a mouse model for metastatic pancreatic cancer, an attenuated strain of <i>L. monocytogenes</i> showed greater infection and replication in metastatic lesions than in primary tumors and normal tissues. In the mouse model, attenuated <i>L. monocytogenes</i> linked to rhenium-188 (^{188}Re) decreased the number and size of metastatic lesions compared with the bacterium or ^{188}Re alone. Next steps include testing the ^{188}Re-labeled <i>L. monocytogenes</i> in xenograft models for pancreatic cancer.</p> <p>Advaxis Inc.'s Lovaxin C (ADXS11-001), a live <i>L. monocytogenes</i>-based immunotherapy expressing HPV type 16 E7, is in Phase II testing to treat cervical cancer and Phase I/II testing to treat colorectal and head and neck cancers.</p> <p>Aduro BioTech Inc.'s CRS-207 (ANZ-207), a live, attenuated strain of <i>L. monocytogenes</i> that expresses human mesothelin, is in Phase II testing to treat pancreatic cancer and Phase I testing to treat malignant pleural mesothelioma.</p> <p>SciBX 6(17); doi:10.1038/scibx.2013.413 Published online May 2, 2013</p>	Patented by the Albert Einstein College of Medicine of Yeshiva University; available for licensing	<p>Quispe-Tintaya, W. <i>et al.</i> <i>Proc. Natl. Acad. Sci. USA</i>; published online April 22, 2013; doi:10.1073/pnas.1211287110</p> <p>Contact: Claudia Gravekamp, Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y. e-mail: claudia.gravekamp@einstein.yu.edu</p> <p>Contact: Ekaterina Dadachova, same affiliation as above e-mail: ekaterina.dadachova@einstein.yu.edu</p>